Login Register Cart 0
Generic placeholder image

Anti-Infective Agents

Editor-in-Chief

ISSN (Print): 2211-3525
ISSN (Online): 2211-3533

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

In Silico (3D-QSAR) Designed, Study, Synthesis and Anti-tubercular Evaluation of Pyrazolo-Pyrimidine Derivatives

Author(s): Pratiksha Chhatbar, Kaushik Pambhar, Vijay Khedkar, Anamik Shah and Ranjan Khunt*

Volume 18, Issue 2, 2020

Page: [135 - 143] Pages: 9

DOI: 10.2174/2211352517666190225143923

Abstract

Background: A 3D-QSAR study based on CoMFA and CoMSIA was performed on these pyrazole-pyrimidine derivatives to correlate their chemical structures with the observed activity against M. tuberculosis.

Objectives: The current research aimed to synthesize and evaluateed pyrazole-pyrimidine based antitubercular agents by an in vitro microbial study based on our previously reported 3D-QSAR.

Methods: The designed molecules were synthesised via chalcone intermediate and cyclisation using guanidine and urea. The molecules were then characterized by various spectroscopic methods like IR, MASS, 1H-NMR, 13C-NMR and in vitro evaluation against M. tuberculosis H37Rv. They were further evaluated under anaerobic condition and their intracellular assay was studied. The compounds were further examined for cytotoxicity towards eukaryotic cells.

Results: Compounds 3a, 3c and 3i were found to be the most effective against M. tuberculosis H37Rv, with IC50 of 16μM, 13μM and 15μM, respectively.

Conclusion: The designed strategy, to enhance the antitubercular activity against M. tuberculosis H37Rv, was proved fruitful. On considering the overall data, the promising results would be useful to design the next target with improved efficacy and potency of compounds for further medicinal importance.

Keywords: 3D-QSAR, hybrid molecules, pyrazolo-pyrimidine, anti-tubercular agents, H37Rv, M. tuberculosis.

Graphical Abstract

[1]
Siroka, Andrew 2017 Global Tuberculosis Report. 2018.
[2]
Tb, M.; Mtb, X.; Who, N. What is multidrug-resistant tuberculosis (MDR-TB) and how do we control it?; World Health Organization, 2019.
[3]
Shi, R.; Itagaki, N.; Sugawara, I. Overview of anti-tuberculosis (TB) drugs and their resistance mechanisms. Mini Rev. Med. Chem., 2007, 7(11), 1177-1185.
[http://dx.doi.org/10.2174/138955707782331740] [PMID: 18045221]
[4]
Lougheed, K.E.A.; Taylor, D.L.; Osborne, S.A.; Bryans, J.S.; Buxton, R.S. New anti-tuberculosis agents amongst known drugs. Tuberculosis (Edinb.), 2009, 89(5), 364-370.
[http://dx.doi.org/10.1016/j.tube.2009.07.002] [PMID: 19699151]
[5]
Saini, M.S.; Kumar, A.; Dwivedi, J.; Singh, R. a review : biological significances of heterocyclic compounds. Int. J. Pharm. Sci. Res., 2013, 4, 66-77.
[6]
Selvam, T.P.; James, C.R.; Dniandev, P.V. A mini review of pyrimidine and fused pyrimidine marketed drugs., 2012, 2, 1-9.
[7]
Horrocks, P.; Pickard, M.R.; Parekh, H.H.; Patel, S.P.; Pathak, R.B. Synthesis and biological evaluation of 3-(4-chlorophenyl)-4-substituted pyrazole derivatives. Org. Biomol. Chem., 2013, 11(29), 4891-4898.
[http://dx.doi.org/10.1039/c3ob27290g] [PMID: 23779132]
[8]
Harikrishna, N.; Isloor, A.M.; Ananda, K.; Obaid, A.; Fun, H.K. Synthesis, and antitubercular and antimicrobial activity of 1′-(4-chlorophenyl)pyrazole containing 3,5-disubstituted pyrazoline derivatives. New J. Chem., 2016, 40, 73-76.
[http://dx.doi.org/10.1039/C5NJ02237A]
[9]
Xu, Z.; Gao, C.; Ren, Q.C.; Song, X.F.; Feng, L.S.; Lv, Z.S. Recent advances of pyrazole-containing derivatives as anti-tubercular agents. Eur. J. Med. Chem., 2017, 139, 429-440.
[http://dx.doi.org/10.1016/j.ejmech.2017.07.059] [PMID: 28818767]
[10]
Kumar, H.; Saini, D.; Jain, S.; Jain, N. Pyrazole scaffold: a remarkable tool in the development of anticancer agents. Eur. J. Med. Chem., 2013, 70, 248-258.
[http://dx.doi.org/10.1016/j.ejmech.2013.10.004] [PMID: 24161702]
[11]
Ajay Kumar, K.; Jayaroopa, P. Pyrazoles: Synthetic strategies and their pharmaceutical applications-an overview. Int. J. Pharm. Tech. Res., 2013, 5, 1473-1486.
[12]
Hagmann, W.K. Perspective.The many roles for fluorine in medicinal chemistry. J. Med. Chem., 2008, 51(15), 4359-4369.
[13]
Gillis, E.P.; Eastman, K.J.; Hill, M.D.; Donnelly, D.J.; Meanwell, N.A. Applications of Fluorine in Medicinal Chemistry. J. Med. Chem., 2015, 58(21), 8315-8359.
[http://dx.doi.org/10.1021/acs.jmedchem.5b00258]
[14]
Ansari, A.; Ali, A.; Asif, M. Review: biologically active pyrazole derivatives. New J. Chem., 2016, 41, 16-41.
[http://dx.doi.org/10.1039/C6NJ03181A]
[15]
Bhatt, J.D.; Chudasama, C.J.; Patel, K.D. Pyrazole clubbed triazolo[1,5-a]pyrimidine hybrids as an anti-tubercular agents: Synthesis, in vitro screening and molecular docking study. Bioorg. Med. Chem., 2015, 23(24), 7711-7716.
[http://dx.doi.org/10.1016/j.bmc.2015.11.018] [PMID: 26631439]
[16]
Khunt, R.C.; Khedkar, V.M.; Chawda, R.S.; Chauhan, N.A.; Parikh, A.R.; Coutinho, E.C. Synthesis, antitubercular evaluation and 3D-QSAR study of N-phenyl-3-(4-fluorophenyl)-4-substituted pyrazole derivatives. Bioorg. Med. Chem. Lett., 2012, 22(1), 666-678.
[http://dx.doi.org/10.1016/j.bmcl.2011.10.059] [PMID: 22104148]

Rights & Permissions Print Cite
Article Metrics
10
© 2024 Bentham Science Publishers | Privacy Policy